THOM, GEORGE,IRVING, LORRAINE,PERKINTON, MICHAEL,SCHOFIELD, DARREN
申请号：
ARP170101504
公开号：
AR108663A1
申请日:
2017.06.01
申请国别(地区):
AR
年份:
2018
代理人:
摘要：
Claim 1: an Antibody or an Antigen binding Fragment of the same, wherein the synuclein binds to human with a KD of less than 500 PMSpecifically binds to the region between approximately 102 approximately 130 amino acid and the amino acid within the c-terminal region of - synuclein to humanAnd reduces the dispersion of - synuclein in vivo.Claim 8: The Antibody or Antigen binding Fragment of the same, according to any one of claims 1 to 6, wherein the antibodyOr a fragment of Antigen binding, the Cor has at least one selected from: (i) The H - SEQ ID no. 5 of the CDR1, CDR2 (ii) H - The SEQ ID no. 6, (iii) The H - CDr3 of SEQ ID no. 7(iv) The L - SEQ ID no. 9 of the CDR1, CDR2 L (V) of the SEQ ID no. 10, (VI) L - CDr3 of SEQ ID no. 11.Claim 46: a method of treatment or prevention of a disease of the central nervous system (CNS) in a patient,Wherein Said method comprises administering to the patient an Antibody or an Antigen binding Fragment of the same, according to any one of claims 1 to 41.Claim 50: a Pharmaceutical composition which comprises an Antibody or an Antigen binding Fragment of the same, according to any one of claims 1 to 41,And a pharmaceutically acceptable excipient.Claim 51: an isolated Nucleic Acid Molecule, which encodes the Antibody or Antigen binding Fragment of the same,According to any one of claims 1 to 41.Reivindicación 1: Un anticuerpo, o un fragmento de unión al antígeno del mismo, caracterizado porque se une a la a-sinucleína humana con una KD de menos de 500 pM, específicamente se une a la región comprendida entre aproximadamente el aminoácido 102 y aproximadamente el aminoácido 130 dentro de la región C-terminal de la a-sinucleína humana, y reduce la dispersión de a-sinucleína in vivo. Reivindicación 8: El anticuerpo, o un fragmento de unión al antígeno del mismo, de acuerdo con cualquiera de las reivindicaciones 1 a 7, caracterizado porque el anticuerpo, o un fragmento de unión al antígeno del mismo, tiene por lo menos una CDR selecciona
